Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 19880065.
- Also identified by DOI 10.1016/S1470-2045(09)70241-4.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Asia has a disproportionately large share of the world's hepatocellular carcinoma (HCC), mainly because of the endemic status of chronic hepatitis B and C viruses, which leads to liver cirrhosis and an increased risk of HCC. This etiological factor presents important opportunities for prevention, early detection, diagnosis, and treatment of HCC. This consensus statement reviews the available medical evidence for management of HCC in Asia, and gives treatment recommendations that are adapted to resource availability in this diverse region with disparate health-care delivery systems.
Medical subject headings
- Antineoplastic Agents
- Carcinoma, Hepatocellular
- Developing Countries
- Digestive System Surgical Procedures
- Liver Neoplasms
- Medical Oncology
- Preventive Health Services